Related Experiment Video
Updated: Jul 4, 2026
11:12
Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
Published on: September 18, 2012
Perceived risk, resources, and perceptions concerning driving and epilepsy: a patient perspective
John O Elliott1, Lucretia Long
1Department of Neurology, Ohio State University, Columbus, OH 43210, USA.
Epilepsy & Behavior : E&B
|June 10, 2008
Summary
Many people with epilepsy are not fully honest about seizure frequency to continue driving, impacting patient counseling. Understanding attitudes toward driving is crucial for epilepsy management and safety.
Area of Science:
- Neurology
- Public Health
- Behavioral Science
Background:
- Epilepsy management often involves restrictions on driving.
- Previous research focused on identifying drivers who disregard medical advice.
- Understanding patient attitudes and beliefs is vital for effective counseling.
Purpose of the Study:
- To analyze health behavior, attitudes, and beliefs of individuals with epilepsy regarding driving.
- To identify predictors of driving behavior in persons with epilepsy.
Main Methods:
- A 46-item questionnaire was administered to 213 individuals with epilepsy.
- Data collected included honesty about seizure frequency, driving accidents, and various health belief scales.
Main Results:
- 19% admitted dishonesty about seizure frequency to drive; 26% reported seizure-related accidents.
- No significant gender or residence differences were found in safety concerns or attitudes.
- Key predictors of driving behavior included race/ethnicity, employment, dishonesty, and specific health beliefs.
Conclusions:
- Honesty about seizure frequency is a significant issue for individuals with epilepsy who drive.
- Health beliefs and demographic factors influence driving behavior.
- Tailored communication strategies are needed for effective patient counseling on driving safety.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
01:13Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types: